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ABSTRACT 
 
Human Gingival Mesenchymal Stem Cells and Self-Assembling Peptide PuraMatrixTM 
Scaffold for Bone Formation   
June 2014 
Don Dinh Do 
M.S., NOVA Southeastern University College of Dental Medicine  
D.D.S., New York University College of Dentistry 
Directed by: Professor Umadevi Kandalam, Pediatric Dentistry, NSU College of Dental 
Medicine  
 
Purpose: Among various craniofacial defects, cleft palate is the most common congenital 
birth defect. Reconstruction of bony parts in the hard palate is important to preserve 
normal craniofacial growth. Autologous bone grafting is associated with donor site 
morbidity, extensive healing time, and scar formation. Tissue engineering techniques 
remain a viable option for the repair and reconstruction of bone. In this study, human 
gingiva-derived mesenchymal stem cells (HGMSCs) were used in combination with a 
self-assembled injectable hydrogel scaffold PuraMatrixTM for their ability to regenerate 
bone. The ability of bone formation of the cell-gel combination was assessed in rat 
ectopic bone formation system. Methods: HGMSCs were cultured under standard culture 
conditions. Cells obtained from 3rd passage were encapsulated in 0.5% PuraMatrixTM 
gel. The cell proliferation was monitored at day 1, 3, 5, and 7 using Live/Dead cell assay. 
Osteogenesis was determined by assessing matrix mineralization at 4 weeks. The cell-gel 
constructs were implanted in subcutaneous pockets of 4-week-old Sprague Dawley rats. 
The bone formation was followed at 2 and 4 weeks using histological and computed 
tomography scans. Results: Cells encapsulated in PuraMatrixTM were viable and cell 
growth was observed from day 3. Matrix mineralization was observed at 4 weeks in cell-
gel inserts. The bone formation was  
	  
	  
	   viii	  
observed after 4 weeks of implantation. Conclusion: The self-assembled injectable 
PuraMatrixTM scaffold in combination with HGMSCs can support bone tissue growth in 4 
weeks.  
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CHAPTER 1: INTRODUCTION          
 
1.1 Background 
 
Cleft palate is a congenital birth defect affecting soft and hard tissue of the craniofacial 
complex with an incidence of 1:700 births yearly [1, 2] (Figure 1.1). The incidence 
correlates with geographic origin, ethnic background, and socio-economic status. Palatal 
fusion is normally completed in man as bilateral palatal shelves grow and fuse to 
complete the palate formation at week 12. However, clefting of the palate is formed when 
there is a disturbance in palatogenesis process [1]. There are many variations of cleft 
palate and significant morbidities associated with this disorder resulting in a Health 
Burden [3].  
Cleft lip and palate patients present with an extensive lists of challenges. Due to the 
anatomical imbalances and abnormal craniofacial growth and development, patients 
present with complications such as feeding problems, middle ear infection, speech 
abnormality, poor dentition, and psychosocial development. A craniofacial team is 
required to rehabilitate these patients providing a multidisciplinary approach with 
surgical and non-surgical life long therapies [4].  
 
 
Figure 1.1: Cleft palate photograph. Extra oral and intraoral photograph of patient with 
unilateral cleft lip and palate.  
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1.2 Current surgical procedures 
 
The available surgical procedures for the repair of cleft palate require a series of 
procedures throughout the course of a child’s life to guide their craniofacial development 
(Table 1.2). The abnormality of children with cleft lip and palate requires such extensive 
intervention consisting of multiple surgical approaches in order to establish proper 
maxillofacial growth [2].  
 
Current Surgical Procedures 
Age Surgical Procedure References 
3-6 months Definitive cleft lip repair to allow normal growth of 
nasiolabial complex 
Behnia et al, 
2009 
10-14 
months 
Gingivoperiosteoplasty, closure of nasal mucosa and 
mucosa of the hard and soft palate to close oral-nasal 
communication; aiding infant in feeding, speech 
development, growth 
Meng et al, 
2009 
5-10 years Bone graft is performed to close hard tissue providing 
arch stability for the developing dentition 
Meng, 2009 
Greenwald 2001 
13-18 years Orthognathic surgery for maxilla bone advancement 
as needed to provide proper jaw relationship 
Meng 2009 
Conjero 2006 
13-18 years Rhinoplasty is performed to provide cosmetic 
corrections to the midface 
Witt, Hardest, et 
al, 1993 
 
Table 1.2: Current surgical procedures 
 
Early in the child’s life, soft tissue procedures offer limited repair leaving severe 
abnormalities in the maxillofacial growth requiring hard tissue repair. Therefore, the 
main procedure of cleft palate repairs the bone graft to provide closure of hard tissue. The 
objectives of hard tissue closure is to provide support for unerupted teeth and teeth 
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adjacent to the cleft, provide support for the lip and nose to improve symmetry, form 
stable continuous maxillary alveolar ridge, closure of oro-nasal fistula, support elevation 
of the alar base, and stabilization of the pre-maxilla in bilateral cases [1, 5-7]. In current 
clinical practice of cleft repair in humans, autologous bone grafts are utilized during the 
hard tissue surgery [2].  
1.3 Complications 
 
Autologous grafts are considered the “gold standard,” however requiring huge amount of 
bone [2, 4, 6, 8, 9]. Therefore autografts have limited availability and the harvest is often 
associated with donor-site morbidity [4], with the consequent drawbacks in terms of 
costs, procedure time, and patient discomfort [6, 10]. After repair, children still face 
abnormal maxillofacial growth resulting in midface deficiency requiring maxilla 
expansion and orthognathic surgery to improve facial appearance and dental function. 
Due to these limitations and disadvantages, alternative therapeutic methods are warranted 
to provide better treatment for children. On the other hand, allografts, the alternative to 
autografts, are being used in clinical practice over the last three decades [6, 11, 12]. 
However, allografts may carry with it the risk of disease transmission results in slow rate 
of new bone formation, may elicit immune response [13] 
1.4 Paradigm shift  
 
Tissue engineering techniques as alternative to traditional methods have emerged recently 
offering novel approaches to produce bone graft substitutes.  
1.5 Tissue engineering 
  
Tissue engineering/regenerative medicine strategies involves replacement of damaged or 
diseased tissue to maintain or improve tissue function applying biological and 
engineering principles [14, 15]. Essentially cell based tissue regeneration mimics natural 
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way of tissue regeneration. The cell based tissue engineering triad consists of stem cells, 
extracellular matrices (scaffolds), and pertinent biologic signaling molecules (Figure 1.5) 
[14, 16]. 
  
Figure 1.5: Tissue engineering concept. Tissue engineering is the summation of three 
components; scaffolds, cells, and signals.  
 
1.6 Cells 
 
Mesenchymal stem cells (MSCs) have emerged as potential cell sources in all cell based 
therapies [8, 17-20]. MSCs are adult stem cells that have ability to differentiate into a 
variety of cell types including osteoblasts, chondrocytes, and adipocytes. MSCs have a 
great capacity for self-renewal while maintaining their multipotency [19-21].  
1.7 Signals 
 
Signals and growth factors can stimulate cellular growth, proliferation, healing, and 
cellular differentiation. In regards to tissue engineering, to provide optimal growth and 
repair, scaffold systems can be supplemented with growth factors such as bone 
morphogenetic protein 2, vascular endothelial growth factor, fibroblast growth factor, 
transforming growth factor, insulin-like growth factor, and etc. [22, 23].   
1.8 Scaffolds 
 
A scaffold is a 3D construct that serves as temporary support for the cells that needs to be 
delivered on to the defect site. Ideal scaffold should have intrinsic cell adhesion and 
Cells	  
Signals	  Scaffold	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interaction, porosity to promote cell proliferation and differentiation and exchange of 
nutrients and metabolites, degradation properties such as ability to degrade at the rate that 
tissue is formed, mechanical stability to withstand stress bearing mechanical loads, 
adaptability to irregularities, responsiveness to growth and development changes and 
micro surgically implantable [14, 24-28].  
1.9 Bone tissue engineering:  
 
Traditionally, autologous bone graft is used for bone repair however due to 
aforementioned concerns, tissue-engineering approaches have aroused as cutting-edge 
technology for bone regeneration. Bone tissue engineering is an approach utilizing 
osteogenic cells, osteoinductive signals, and osteoconductive scaffolds. Nevertheless, 
bone repair strategies in adults cannot be applied to the pediatric population as their 
bones are still in the developmental stages [14, 16]. Additionally, special considerations 
must be taken into account as cranial structures develop differently from appendicular 
skeleton and that the cranial structures are derived from neural crest derived MSCs [16]. 
This creates a unique challenge to develop tissue-engineering systems with the ability to 
recapitulate the corresponding craniofacial developmental events and needs. Therefore it 
is essential to select appropriate cell source and scaffold material. In this study, HGMSCs 
have been used as source of cells. 
1.10 Human Gingiva Derived Stem Cells: 
 
Bone marrow stem cells (BMSCs) are traditional stem cell sources [12, 16, 21, 29] for 
bone tissue engineering with the advantages of being an autologous source. However, 
there are several disadvantages as isolation involves invasive procedures. Furthermore 
BMSCs provide low yield of MSC with high variability and limited self-renewal capacity 
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(Figure 1.10) [17, 30]. The other sources of MSCs are from adipose tissue [4], human 
umbilical cord [30], human exfoliated deciduous teeth [31], and human dental pulp [32].  
 
Recently, the human oral mucosa and gingiva has been discovered to be a promising 
alternative cell source for MSCs based tissue engineering [33]. HGMSCs derived from 
gingiva have been shown to be superior than bone marrow derived mesenchymal stem 
cells (BMMSC). HGMSCs have been shown to be easier to isolate, uniformly 
homogenous, proliferates faster than BMMSC, displays stability in long-term cultures, is 
not tumorigenic, and is independent of growth factors for expansion [17]. Recent 
evidence showed that HGMSCs are capable of immunomodulatory functions and anti-
inflammatory function [20]. These reports suggest that gingiva derived stem cells may 
reduce healing time, scar tissue formation, and fistula formation [34].   
 
HGMSCs have also recently been considered as an appropriate stem cell source for the 
repair and regeneration of bone in all craniofacial defects. 90% of HGMSCs are derived 
from cranial neural crest cells (CNCC) and 10% from the mesenchyme [19, 20, 35]. 
Neural crest cells are multipotent migratory cells unique to vertebrates that give rise to a 
diverse cell lineage such as melanocytes, neurons, tooth structure, and craniofacial 
cartilage and bone. Notably, post migratory CNCCs preserve stem cells reveal it’s ability 
to regenerate craniofacial structures [19, 36]. Keeping in mind the several advantages of 
HGMSCs, this study intended to investigate the bone regeneration/formation capacity of 
HGMSCs.  
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Figure 1.10: Mesenchymal Stem Cells. MSCs retain ability to self-renew and 
differentiate.  
 
 
1.11 Injectable hydrogels 
 
Traditional bone grafting techniques have complications of a large surgical scar, 
increased pain, and extended healing time. Hydrogels scaffold materials are attractive 
sources as they have structural similarity to the macromolecular-based components in the 
body and are biocompatible. Injectable hydrogels are novel strategy for local delivery of 
stem cells (Figure 1.11) [14, 24, 25]. Additionally these materials act as a dynamic liquid 
support to carry living cells, drugs and growth factors. They may be natural [14, 24] or 
synthetic [14, 24, 26] and have the ability to deliver cells at the defect site without 
inflammatory reaction with minimal immune response and reduce scar formation [24, 25].   
 
 
 
Figure 1.11: Injectable peptide hydrogel scaffold. Scaffold with characteristic to 
deliver cells via injectable method.   
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1.12 PuraMatrixTM 
 
PuraMatrixTM is a commercially available self-assembled synthetic peptide hydrogel that 
is amphiphilic in nature. The peptide hydrogel is composed of 16 peptides with a 
repeating sequence of arginine, alanine, asparte, and alanine (RADARADARADARADA 
or RAD16) (Figure 1.12A). The amino acid sequence consists of alternating hydrophobic 
and hydrophilic side groups (13, 14, 19). Most notably PuraMatrixTM, upon contact with 
physiological conditions can instantly polymerize forming matrices providing three-
dimensional architecture to the cells [27, 34, 37-41] (Figure 1.12B). The nanofiber 
structures of these peptides (<10nm in diameter with several times thinner than the cells) 
and the porous structure (5-200nm) enable the cells to grow within the gel. Furthermore, 
these fibers surround the cells in a manner similar to the natural extracellular matrix [42, 
43]. Unlike the other extracellular matrix proteins such as collagen, laminin, and poly-
glycosamine materials, it is not animal derived. Previous studies have demonstrated that 
PuraMatrixTM can support cell attachment, proliferation, and differentiation in to various 
cell types [26, 44-47]. Also, the viscosity of the hydrogels allows injectable applications 
to fill irregular shapes and voids as presented by cleft palate defects to maximize cell 
adhesion and interaction enhancing bone regeneration [37]. This suggests that the 
PuraMatrixTM scaffold system is favorable to deliver the human gingival stem cells for 
the repair of bony defects including cleft palate.  
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Figure 1.12A: PuraMatrixTM structure. RAD16 amino acid make up.  
 
 
    
 
Figure 1.12B: PuraMatrixTM gel. 
 
 
1.13 Objective 
 
The objective of this study is to evaluate bone formation ability of a novel nano 
composite cell-scaffold system. Self-assembled nanofibrous peptide scaffolds in 
combination with HGMSCs were used for this study. Upon successful establishment, this 
scaffold system will be used to repair the hard palate.  
1.14 Specific Aims and Hypothesis  
 
1.14.1 Specific Aim 1: Characterizing cell-gel constructs of HGMSCs and 
PuraMatrixTM 
 
The first specific aim of this study was to evaluate cellular characteristics of HGMSCs 
encapsulated in the peptide hydrogel scaffold, PuraMatrixTM, compared to cells cultured in 
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monolayer. Utilizing in vitro studies; cell proliferation, cell viability, confirmation of 
MSCs properties, and osteogenesis differentiation will be observed.  
 
1.14.2 Specific Aim 2: Evaluate Bone formation capacity of HGMSCS embedded in 
PuraMatrixTM hydrogel  
 
The cells were transplanted on to the subcutaneous sites of rats by either injected or 
implanted. In Injectable method, HGMSCs were cultured using standard culture 
conditions and induced with osteogenic differentiation medium for 9 days loaded onto 
PuraMatrixTM gel and injected in subcutaneous pockets of rats. In implantation method, 
HGMSCs were encapsulated and cultured in PuraMatrixTM hydrogel (3-D cultures) for 9 
days and implanted in subcutaneous pockets of rats. The bone formation was monitored 
at 2 weeks and 4 weeks interval.  
1.14.3 Hypothesis 
 
Null Hypothesis (H0): There is no difference in ectopic bone formation via subcutaneous 
implantation between HGMSCs seeded PuraMatrixTM scaffold compared to 
PuraMatrixTM scaffold only when measured by CT scans and histological analysis at 4 
weeks.   
Alternative Hypothesis 2 (H1): There is significantly more ectopic bone formation via 
subcutaneous implantation of HGMSCs seeded PuraMatrixTM scaffold compared to 
PuraMatrixTM scaffold only when measured by CT scans and histological analysis at 4 
weeks.   
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1.15 Location of study 
 
This study was conducted at the Craniofacial Research Center (Room #7391), College of 
Dental Medicine, 3200 South University Drive, NOVA Southeastern University, Fort 
Lauderdale, FL 33328.  
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CHAPTER 2: MATERIAL AND METHODS        
 
2.1 Overall study design 
 
The study design consisted of two phases. The first phase was to isolate HGMSCs and to 
encapsulate HGMSCs in PuramatrixTM scaffold and monitor the cell growth and 
osteogenic potential. The second phase of the study investigates the in vivo efficacy of 
bone formation of HGMSCs in combination with the self-assembled scaffold. 
2.1.1 Specific Aim 1: Characterization of PuraMatrixTM Scaffold impregnated with 
HGMSCs 
 
Healthy discarded human gingival tissue was obtained with the informed consent from 
the patients undergoing the flap surgeries and crown lengthening procedures at NSU 
Dental Clinics. Mesenchymal stem cells were isolated from the gingival tissue (NSU IRB 
#02071304) and expanded under standard culture conditions. The panel of surface 
makers (CD73+, CD90+, CD105+ and CD34-ve) was measured on regular basis (to each 
batch of the MSCs) to confirm their stem cell nature. Our pilot studies have shown that 
the cells encapsulated in 0.5% PuramatrixTM have enhanced proliferation over 1% 
PuraMatrix scaffold. Therefore, we propose to use 0.5% PuraMatrix for this study. We 
investigated cell proliferation and differentiation of HGMSCs within the hydrogel 
scaffold (Figure 2.1.1).  
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Figure 2.1.1: Specific Aim flow chart 
 
 
2.1.2 Specific Aim 2: In vivo evaluation of bone formation ability of composite 
injectable cell- scaffold system 
 
Two types of cell delivery methods were evaluated for bone formation ectopic bone 
formation model. Method 1. Cells in monolayers (2-D cultures) were cultured and 
guided for osteogenic differentiation for 9 days. On Day 10 the cells were mixed with 
PuramatrixTM and injected using a syringe with 20 gauze needles in subcutaneous sites 
Method 2. The cells encapsulated in 0.5% PuramatrixTM, cultured and differentiated (3-D 
cultures), and delivered in subcutaneous sites. Detailed experimental procedures were 
given below. The bone formation was followed at 2 and 4 week time intervals. Bone 
growth was assessed with computed tomography (CT) scan and histologically. The 
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results of this subcutaneous model study determined the more suitable implantation and 
delivery mode of cell-scaffold system (Figure 2.1.2).  
 
 
 
 
Figure 2.1.2: Specific Aim 2 flow chart 
 
 
2.2 Materials 
 
Commercially available self-assembled peptide scaffold PuraMatrixTM obtained from 
Corning Life Sciences (Tewksbury, MA) was used for the study. HGMSCs were obtained 
from human gingival tissue from clinic at Nova Southeastern University (Davie, FL) 
upon the approval of institutional review board. For the use of Sprague Dawley rats, 
Institutional ethical clearance was obtained (# 053-468-0121) prior to the commencement  
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of the study. Unless otherwise mentioned, all other necessary chemicals and lab supplies 
required for the study were obtained from Sigma (St. Louis, MS), from VWR 
international (Radnor, PA) respectively. 
 
2.3 Isolation of mesenchymal stem cells from gingival tissue 
 
The gingival tissue obtained from clinic was de-epithelialized and minced into small 
pieces (2x2mm) and rinsed with Dulbecco’s Modified Eagle Medium (DMEM; Life 
technology, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS; Atlanta 
Biologics, Norcoss, GA), 400 mmol/ml L-glutamine, 100 U/ml penicillin, 100 lg/ml 
streptomycin and 1% amphotericine [48]. Mesenchymal stem cells were obtained from 
the gingival tissue using standard procedures [17]. Briefly, cells were digested 
enzymatically using collagenase and dispase for 30 minutes. The first cell suspension was 
discarded to avoid the interference of epithelial cells. The tissue samples were further 
treated with collagenase and dispase and the cell suspension was collected. The 
procedure was repeated twice and the cell suspensions were pooled. The cell suspensions 
were centrifuged and the cell pellet were plated in tissue culture flask and grown under 
standard culture conditions, in a humidified incubator at 37°C and 5% CO2. 
2.4. Cell Culture  
Cells cultured under specific culture conditions were subsequently sub-cultured at 90% 
confluence [5] and expanded. The cells were cultured in growth medium (DMEM, 10% 
FBS and 1% antibiotics) at 37°C and 5% CO2. To ensure uniform cell population first two 
passage cells were kept further expansion and cells from third or fourth passage were 
used for all studies. 
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2.5 Characterization of HGMSCs by surface markers by flow cytometry method 
Cells at the concentration of 106 cells were used to measure the surface markers using 
Miltenyi Kit according to manufacturer’s instruction. The specific markers positive for 
mesenchymal stem CD 73, CD 90 and CD 105 and negative for CD 34 were identified at 
the facilities at University of Miami using a florescent activated cell sorter FACAria IIIu 
(BD Biosciences, San Jose, CA) with adjusted florescence compensation setting negative 
samples were used to set up the thresholds of quadrant markers (Figure 2.5).   
 
 
 
Figure 2.5: Flow cytometry. BD FACSAria IIIu 
 
2.6 HGMSCs encapsulation and culture in PuramatrixTM (cell–gel Constructs 3D 
culture) scaffold: 
 
The cells (HGMSCs) from 3rd or 4th passage were used for all of experiments. Based on 
our pilot studies and previous literature [49] support we have chosen to use 0.5% 
PuramatrixTM for all the experiments.  The encapsulation method was followed according 
to manufacturer’s instructions. Briefly, the cells were suspended in 20% filter sterile 
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sucrose solution (isotonic) and combined at 1:1 with 1% PuramatrixTM. To form cell-
hydrogel complex, 500 µL of standard culture medium was added to each well of a 24- 
well tissue culture plate, and cell- gel mix was slowly dropped in to each well of 24 well 
plate. To prevent drying of the surface of hydrogel, the culture medium was carefully 
layered and incubated in 37ᵒC at 5% CO2 for 30 min. The medium was replaced after 
designated time to equilibrate the physiological pH conditions. The cell-gel constructs 
were further incubated under standard culture conditions and cell morphology was 
monitored under phase contrast microscope on daily basis. The growth pattern was 
carefully monitored to check whether encapsulation of HGMSCs in the peptide hydrogel 
scaffold is damaging.  
2.7 Scanning Electronic Microscopy studies 
The cells were encapsulated in 0.5% PuramatrixTM. PuramatrixTM hydrogel alone and the 
cell gel constructs at day 3 and Day 7 were used for the study. The cell-gel constructs 
were washed with PBS and were fixed in 2% gluraldehyde solution and dehydrated in 
graded series of alcohol and snap fractured and critical point dried from CO2. Samples 
were mounted and gold sputtered and examined under SEM (Quanta 200; FEI, Hillsboro, 
OR, USA) (Figure 2.7).  
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Figure 2.7: Scanning Electron Microscope: FEI Quanta 200 
 
2.8 Cell Viability 
 
2.8.1 WST assay 
 
Cell proliferation was assessed by addition of WST-1 (2-4-iosophenyl)-3-4-nitorphenyl)-
5-(2,4 disulfophenyl)-2H-tetrazolium, monosodium salt) reagent to a 1:10 final 
concentration. WST-1 cell proliferation assay (Roche, Indianapolis, IN, USA) is a 
mitochondrial activity assay. WST reagent is a soluble tetrazolium salt that can react with 
metabolically active cells and gives a deep red color.  96 well plates were used for this 
assay, in order to prepare for cell- gel constructs 200 µl of growth medium was placed in 
each well of the plate. Cells suspended in 0.5% gel were slowly released in to the growth 
medium. After 30 minutes of the incubation at 37ᵒC the growth medium was replaced to 
and cells were fed with new growth medium and gelation was examined under 
microscope. The cell-gel constructs were finally incubated at 37ᵒC, 5% CO2.  The assay 
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was conducted at 24, 48 and 72 hours’ time intervals and the absorbance was measured 
using micro-plate reader (Figure 2.8.1). The cell viability was expressed in percentages.  
 
 
Figure 2.8.1. WST Assay. 
 
2.8.2 Live Dead Cell Assay 
 
Cell viability of the HGMSCs in PuraMatrix was assessed by another assay called 
Live/Dead cell assay (Molecular Probes, Carlsbad, CA) (Figure 2.8.2). Cells were grown 
in PuraMatrix and cell proliferation was followed at 1, 3, 5, and 7 day intervals. Live 
Dead cell assay kit provides two molecular probes, calcein AM and ethidium 
homodimer-1 (Eth-D) for simultaneous visualization of the live cells and dead cells. Live 
Cells emit Green Fluorescence when calcein AM enters the cells and is hydrolyzed to 
calcein by intracellular esterase. Eth_D 1 enters to nucleic acids to produce bright red 
fluorescence. 
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Figure 2.8.2: Live/Dead Cell Assay: Olympus IX51 
 
 
2.9 In vitro confirmation of osteogenic differentiation  
 
PuraMatrixTM in combination with stem cells can induce osteogenic differentiation in the 
presence of osteogenic supplements [27]. We have monitored the osteogenic 
differentiation of cells in the constructs at weekly intervals. For the differentiation assays 
24- well plates were used. The cells suspended in 20% of sterile sucrose (250 µL) with 
250 µL of 1% PuraMatrixTM and dropped slowly in to growth medium in which the 
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scaffold can self-assemble to acquire gel shape. The gelation was observed under 
microscope. The gene expression of osteogenic markers was investigated using RT PCR 
and matrix mineralization was monitored at 1, 2 and 3 weekly intervals. 
 
2.9.1 Gene expression assay (RT PCR)  
 
The cell-gel constructs were induced with osteogenic supplements after 5 days of culture 
period. The constructs with only growth medium were considered as control. The 
constructs incubated for 2 weeks was assessed for gene expression studies. Briefly, the 
cells were released from the gel by mechanical disruption and RNA was extracted using 
Trizol (Life Technologies, Carlsbad, CA) method according to manufacturer’s instruction. 
RNA was quantified and cDNA was measured using to standard protocols. Semi-
Quantitative PCR was conducted using specific primers (Table 2.8.1) and the PCR 
products were separated by 2% agarose gel and the relative density was measured using a 
densitometry analysis. 
 
Gene     Sequence 
Col I (sense)                  5'-ctgaccttcctgcgcctgatgtcc-3' 
Col I (antisense)            5'-gtctggggcaccaacgtccaaggg-3 
ALP (sense)                   5'-ccacgtcttcacatttggtg-3' 
ALP (antisense)             5'-agactgcgcctggtagttgt-3' 
OPN (sense)                   5'-tgaaacgagtcagctggatg-3' 
OPN (antisense)             5'-tgaaattcatggctgtggaa-3' 
beta-actin (sense)            5'-catgtacgttgctatccaggc-3' 
beta-actin (antisense)      5'-ctccttaatgtcacgcacgat-3' 
 
Table 2.9.1 Specific primers  
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2.9.2 Matrix mineralization using Alizarin Red Stain 
 
The monolayer cells and cells encapsulated in PuraMatrixTM were investigated and 
compared for their osteogenic potential. Matrix mineralization was monitored 
sequentially on weekly basis. The calcium deposition was confirmed by staining the cells 
with Alizarin red S staining protocol. Briefly, cell in monolayer or constructs cultured in 
osteogenic medium for 4 weeks were fixed with 10% formalin for 30 minutes at room 
temperature and then washed with phosphate-buffered saline for 5 minutes followed by 
10 minutes of incubation with 1% alizarin red solution (Poly Scientific Corp., Bay Shore, 
N.Y.) incubated for 10 minutes at room temperature. Slides were then washed with 
running tap water for 5 minutes and left to dry. The same procedure were performed for 
undifferentiated mesenchymal stem cells [5]. 
 
2.10 In vivo study methodology 
 
2.10.1 Animal subjects 
 
For this study, 4-5 week Sprawley Dawley male rats were chosen (2.10.1). They were 
kept in animal holding facility in separate cages receiving adequate water and food 
pellets under automatically controlled temperature and lighting. Animals were allowed to 
acclimate to environment for 1-3 days. Pre-operative weight and length were measured. 
All intervention and care followed International Animal Care and Use Committee’s 
approved protocol.    
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Figure 2.10.1: Sprague Dawley rat. 4-week old male 
 
2.10.2 Anesthesia 
Intramuscular injections of 1mg/kg intraperiotoneal injection of 1:10 Xylazine: Ketamine 
solution was given prior to the surgery (Table 2.10.1) [50, 51] . Upon the onset of 
anesthesia, rat subjects were transported from animal facility to surgical lab. Repeated 
dosages of 0.5mg/kg were administered as needed per procedural protocol established in 
our research laboratory.  
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10ml 1:10 Xylazine: Ketamine anesthetic solution 
Xylazine 20mg/ml 2.5 ml 
Ketamine 100mg/ml 3.75 ml 
Sterile Water 3.75 ml 
 
Table 2.10.1: Veterinary anesthetic concentration  
 
2.10.3 Cell Culture and differentiation 
 
Cells necessary for animal experiments were cultured and differentiated in two different 
methods. For injectable mode of transplantation monolayer cell cultures were guided to 
differentiate for 9 days and on day 10 the cells were used for injections. The cells used 
for implantation method were encapsulated in PuramatrixTM and induced with osteogenic 
supplements for 9 days and on 10th day the cell- gel constructs were implanted in the 
subcutaneous pouches at dorsum of the rat. 
2.10.4 Subcutaneous implantation/ectopic bone formation 
 
Total six rats (4-5week/200-250g) were used for this experiment. The rats were divided 
into three groups. 1. Control (without intervention) 2. Cells encapsulated in PuraMatrixTM 
and implanted subcutaneously (Preformed gel) 3. Cells grown in 2 D cultures were mixed 
with PuraMatrixTM instantaneously and injected (Injectable group). Intravenous injections 
of the immunosuppressant FTY720 (0.05mg/kg) were given to each rat [52] in order to 
prevent transplant rejection. The bone formation ability of each scaffold were analyzed in 
vivo using a subcutaneous pouch model described [53]. Briefly, six pouches were made 
by blunt dissection in subcutaneous sites [12]. The cells delivered either implantation 
mode or injectable mode.  
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Cell Delivery through implantation mode: Up to 0.5 x106 cells were encapsulated in 
0.5% PuraMatrixTM and the cell-scaffold mix were filled in the subcutaneous defect. The 
pouches were closed with silk sutures and monitored for recovery.  
Cell Delivery by injectable mode: The cells cultured as monolayers (2D cultures) were 
osteogenically differentiated up to 9 days and on 10th day the cells were trypsinized and 
dislodged from the culture flask mixed with PuraMatrixTM gel and injected using a 
disposable syringe delivered through 20 G needle. 
 
 
Figure 2.10.4A: Injectable group diagram and surgical photograph 
 
 
Figure 2.10.4B: Preformed group diagram and surgical photograph 
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2.10.5 Post-operative care 
 
Post-operative care was provided with buprenorphine for analgesia for 48 hours and with 
antibiotics, trimethoprim/sulfamethoxazole, for 10 days at 3mcg/kg [23]. A soft diet was 
prepared and provided for rats in the form of moist food pellets for 24-48 hours per 
animal care protocol established in our research laboratory. Rats were evaluated 
frequently for any signs of inflammation or necrosis [54] 
2.11 Bone analysis 
 
2.11.1 CT scans 
 
CT scans were utilized to monitor bone formation and growth. Panoramic scans were 
taken for evaluation at 2 weeks and 4 weeks post-surgery. The relative bone areas were 
measured by CT scan using i-Cat vision software (Figure 2.10.1). The machine operates 
at 120 kVp and 22.85 mAs, acquiring 300 basis images in a single 20-second revolution 
around the rat head. High resolution scans produces images at 0.2 mm voxel size and 14 
bit gray scale quality allows more shades of gray to increase contrast for easier viewing 
[55]. Each rat was sedated and placed on the same cephalostat and in a standardized 
manner with the head in natural position. Utilizing i-CAT software, 2D scans and 3D 
volumetric representation scans will be used to qualitatively identify and observe bone 
growth [54] . One-millimeter coronal sections of control and experimental findings will 
also be observed for quantitative measurements. Using Image-J software, total number of 
pixels of coronal sections was determined using manipulation color thresholds and 
selected for measurement. Radiopacities were then selected by free hand and measured. 
The extent of new bone area per total area was displayed as a percentage [4, 8, 12, 22].  
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Figure 2.11.1: CT scan  
 
 
2.11.2 Histological analysis:  
 
Following CT scans, animals were euthanized by CO2 asphyxiation and explants were 
dissected at 4 weeks for histological analysis [51]. Samples were fixed in 10% neutral 
buffered formaldehyde for 24 hours and were sent to the Pathology Lab (University of 
Miami, Florida) for further processing. The protocols for microtome sectioning were 
followed using standard protocols. Briefly, after fixation the samples were processed 
using dehydration procedure and he samples were embedded in paraffin wax and 5 µm 
sections were obtained from each sample and the sections were stained with Hematoxylin 
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and Eosin (H&E) staining and further histological analysis [37] was carried out.  The 
injection of the mixture will be done by mixing PuraMatrixTM with the cells at a density 
of 2 x 10⁶ cells/matrix and was injected in the defect [39]. The tissue samples were 
observed by an optical microscope (IX51; Olympus, Tokyo, Japan) and observed 
qualitatively for the appearance of new bone formation and quantitatively for relative 
surface area. Using Image-J software, total number of pixels of histological samples was 
determined using manipulation color thresholds and selected for measurement. Bone 
tissue were then selected by free hand and measured. The extent of new bone area per 
total area was displayed as a percentage [12, 56].  
2.12 Statistical analysis:  
To evaluate differences between or among groups, analysis of variance (ANOVA) will be 
performed. A P-value< 0.05 is selected for significance for the statistical tests. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  
	  
	   29	  
CHAPTER 3: RESULTS           
3.1 Isolation and culture of human gingival cells 
Human gingiva derived stem cells were separated from the gingival tissue using 
enzymatic digestion technique as described in section 2.1. The cell suspension was 
seeded at a density of 2 x 104 cells/cm2 and fed with growth medium (DMEM 
supplemented with 10% FBS and 1% antibiotics). The colony forming units were 
observed after 2 days of seeding. The cells reached 70 to 80% confluency after 7 to 8 
days post seeding (Figure 3.1). The cell population was homogenous; cells were tightly 
adhered with spindle-shaped fibroblasts-like in appearance (Figure 3.1). 
 
  
Figure 3.1. Isolated HGMSCs. A) Freshly isolated HGMSCs from tissue plated on T75 
Tissue Culture Flask. B) Cells at confluence. 
 
3.2 Flow cytometry analysis 
The flow cytometry analysis is a screening assay to identify the panel of surface markers 
to identify MSCs. Cells at third passage were used for the flow cytometry analysis. The 
results confirmed positive for CD 73, CD 90, CD105 (all above 90%) and negative for 
hematopoietic stem cell marker CD 34 (Figure 3.2). 
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Figure 3.2. Flow cytometry analysis. Flow Cytometry shows that cells expressed 
markers characteristic of MSCs; positive for CD105, CD90, CD73, and negative for 
CD14, CD20, CD34, and CD45.  
 
3.3 Cell Growth in PuraMatrixTM (cell –gel constructs 3D model)  
For all our studies cells from passage 3 or 4 were used. The cells encapsulated in 0.5 % 
PuraMatrixTM as described in methodology section. Cell morphology and growth 
characteristics were monitored sequentially under light microscope.   
3.3.1 Light microscopic observation 
Under phase contrast view, HGMSCs seeded on to the PuraMatrixTM nano scaffolds 
showed spherical structures at Day 0. Cell growth was observed from day1. On Day 3 
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cells attained their original spindle shaped. The cells were integrated with in the gel, 
however the cells in the center appeared spherical. The cells in the center appeared 
cluster shaped and on peripheral region attained spindle shaped. On day 7 cells were well 
spread out. Following shows detailed morphological features (Figure 3.3.1 A-C). 
 
Figure 3.3.1A: Light microscopy of HGMSCs at Day 1 and 3. Cells encapsulated in 
PuraMatrixTM hydrogel; Phase contrast images showing the morphology and cell 
proliferation at different time points. A) Day 1- Cells show round structures. B) Day 3- 
Cells attained spindle shape- cell growth can be observed.  
 
Figure 3.3.1B: Light microscopy of HGMSCs at day 5.  A) Cells encapsulated in 
PuraMatrixTM B) Day 5- Cells at peripheral region 
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Figure 3.3.1C: Light microscopy of HGMSCs at day 7. A) Interconnection between 
the cells can be clearly seen B) Cells formed a network with in the nanofiber scaffold. 
 
3.4 Scanning Electronic Microscopy studies 
SEM studies demonstrated that the nanofibers are ~10 - ~ 20 nm. PuraMatrixTM scaffold 
without cells showed a sheath like structure in lower magnification. All observations 
made at cells at day 3 or day 7 cultures (Figure 3.4). The cell bodies appear to be fully 
embedded in the nanofiber scaffold.  Cells at day 3 appeared clusters in the center and 
elongated in the peripheral region. However the cells were intimately interacted within 
the nanofiber. The cells at day 7 the cells showed a linear assembly with in the matrix. 
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Figure 3.4: SEM of PuraMatrixTM and HGMSCs seeded PuraMatrixTM.  A) 
Scanning electron microscopy of PuraMatrixTM scaffold only. A.1 Shows surface 
appearing like a sheet under low magnification, 187x. A.2 Shows peptides appearance to 
be like interwoven nanofibers at higher magnification, 483x. B) Scanning electron 
microscopy of PuraMatrixTM with HGMSC cells. B.1 PuraMatrixTM with HGMSC under 
577x magnification. Shows linear assembly of cells within matrix. B.2 PuraMatrixTM 
with HGMSC under 629x magnification. Shows linear assembly of cells within matrix 
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3.5 Cell growth in PuraMatrixTM (cell –gel constructs 3D model) 
3.5.1 WST Assay 
WST assay is a quantitative assay to measure the cell proliferation. The cell density at 
1x104 was encapsulated in 0.5% PuraMatrixTM with and cell viability was observed at 1, 
2 and 3 days of time interval. Our results revealed that there was slight increase in the 
percent viability within the group. However, there was significant increase in cell 
proliferation at the density of 300,000 on day 3 (Figure 3.5.1). 
 
Figure 3.5.1: WST Assay graph 
3.5.2 Live Dead Cell Assay 
The cells were encapsulated and seeded on to a 96-well plate. For each gel 50µL of 
PuraMatrixTM was used to encapsulate the cells.  The viable and dead cells were 
visualized using a fluorescence microscopy. The viability was investigated at different 
time points (1, 3, 5 and 7 days) indicated that cells were viable at all-time points observed. 
The cell growth started from day 1. At day 3, HGMSCs possessed spindle shape showing 
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typical MSCs feature. Although there was not significant cell proliferation there was an 
increase in number at day 3 (Figure 3.5.2). 
  
Figure 3.5.2: Live/Dead Cell Assay at day 1, 3, 5, and 7. Fluorescent microscope 
staining of cells in PuraMatrixTM hydrogel with Live/Dead staining. A) Day 1-Cells 
encapsulated on day one B) Day 3- Cells with spindle shape and they are spread out 
evenly. C) Day 5– Cells are alive and express growth. D) Day-7 Cells have increased in 
proliferation and show adhesion to fibrous network.  
3.6 Osteogenic differentiation 
 
3.6.1 Expression of osteogenic marker genes 
 
Gene expression of osteogenic lineage specific genes was assessed by semi quantitative 
RT-PCR at 2 weeks’ time interval.  Cells encapsulated in PuramatrixTM induced with 
osteogenic medium showed up regulation of alkaline phosphatase and osteopontin and 
type I collagen gene expressions compared to control cell-gel constructs in culture 
medium (Figure 3.6.1).   
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Figure 3.6.1: RT-PCR Assay 
 
3.6.2 Matrix mineralization using Alizarin Red Stain 
The cells induced with osteogenic differentiation medium were monitored at weekly 
intervals. Cells in the presence of osteogenic factors gingival cells showed formation of 
mineralized nodules or aggregates (Figure 3.6.2) at 4th week of the induction. Calcium 
mineralization was observed at week three after the induction of osteogenic medium. 
This was ells encapsulated in PuraMatrixTM was confirmed by Alizarin red S staining.   
Alizarin red is anthroquinone dye to stain the calcium deposits which are indicators of 
mature osteocytes [57]. The mineral deposition is detected by the orange color nodules. 
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Figure 3.6.2: Alizarin Red Stains of monolayer and encapsulated HGMSCs. 
HGMSCs as monolayer culture (2D) and cells encapsulated in PuraMatrixTM (3-D). The 
morphology of differentiated cells A) Cells in monolayer in osteogenic medium at week 
4 B) Cells induced with OM for 4 weeks and stained with Alizarin Red – orange color 
indicates calcium deposition C) Cells in PuraMatrixTM in OM (clustering of cells can be 
observed) F) 4 weeks -Cells in PuraMatrixTM were stained with Alizarin Red to detect the 
mineral deposit, presence of mineral deposition is observed for cells with in 
PuraMatrixTM gel.      
 
3.7 HGMSCs seeded PuraMatrixTM induces in vivo bone formation  
3.7.1 CT scans 
CT scans show that at 2 and 4 weeks after subcutaneous implantation of HGMSCs seeded 
PuraMatrixTM scaffolds, clusters of radiopacities form at surgical sites (3.7.1A-F). The 
radiopacities suggest that the scaffold system combination has developed ectopic bone 
formation. In the volumetric representation, distinct nodules can be visualized on 
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experimental sides. Using the i-CAT software, cross sections of experimental and control 
side were observed and relative surface area was quantified. Cross section of the control 
side showed normal tissue whereas the experimental side showed radiopacities 
suggesting osteoid formation (Table 3.7.1).   
 
 
 
Figure 3.7.1A: CT Scans of Control and Week 2. Series of images from CT Scan of rat 
subject post surgery using i-CAT vision software showing 2D scans, 3D scans, and 
control and experiment cross sectional slices. A) CT scans of control rat shows no 
radiopacity at week 4. B) Shows 2 week CT scan of rats showing radiopacities starting to 
form.  
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Figure 3.7.1B: CT Scans of week 4. CT scans of rats at 4 weeks time period.   
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Figure 3.7.1C: CT Scans of week 4. F.1) Significant clusters of radiopacities seen in 2D. 
F.2)  Large radiopacity in experimental side suggesting bone formation F.3) Control 
cross-section shows no radiopacities F.4) Cross sectional slice of suspected bone shows 
radiopacity for quantitative measurements.  
 
Number positive for radiopacity/total number of implants 
 Non-seeded PuraMatrixTM HGMScs Seeded 
PuraMatrixTM 
Control 1 0/6  
Preformed 1 0/3 1/3 
Preformed 2 0/3 2/3 
Injectable 1 0/3 2/3 
Injectable 2 0/3 3/3 
Injectable 3 0/3 3/3 
   
Total 0/21 9/15 
% per group 0 0.75 
 
Table 3.7.1A: Radiographic findings. Number of radiopacities observed in control and 
experimental sides.  
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 Preformed Injectable  
 
 PuraMatrixTM HGMSCs + 
PuraMatrixTM 
PuraMatrixTM  HGMSCs + 
PuraMatrixTM  
Cross Sectional 
Area (pixels) 
22,760 ± 2,233 20,983 ± 785 19,735 ± 2899 21,384 ± 870 
Area of 
radiopacity, 
new bone 
formation 
(Pixels) 
0 1,497 ± 1489 0 1,705 ± 915  
Extent of new 
bone formation 
(%) 
0 6.9 ± 6.9 0 9.2 ± 6 
 
Table 3.7.1B: Percentage of radiopacity from CT Scans. Comparison of extent of new 
bone formation of HGMSCs seeded PuraMatrixTM compared to PuraMatrixTM scaffold 
only, which demonstrates evidence of bone formation.  
 
3.7.2 Histological analysis 
Histological analysis shows that 4 weeks after subcutaneous implantation of HGMSCs 
seeded PuraMatrixTM scaffolds, bone formation was present at surgical sites. Using the 
CT scans of radiopaque areas as a guide, tissue samples were surgically removed for 
analysis. There were no signs of infected wound, pus formation, skin necrosis, or dead 
rats during postoperative follow-up observations of the rat. This shows that the hydrogel 
scaffold is biocompatible with the animal and non-toxic. In the histological slides, tissue 
samples of the control side only show connective tissue showing that hydrogel was 
biodegradable. However, in one slide of the control side, a remnant of PuraMatrixTM 
scaffolds is observed (Figure 3.7.2A). In the H&E stained histological slides of the 
experimental sides, bone tissue can be observed with presence of osteoblasts (Figure 
3.7.2B). Using Image-J software, area of bone tissue can be calculated relative to the 
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histological slide. Of the samples, the area of bone formation is present relative to the 
tissue sample size is 15%. Together with the radiographic observations, the data 
supported that the subcutaneous implantations of HGMSCs cells have formed osteoids 
with osteoblasts in PuraMatrixTM hydrogel. 
 
Figure 3.7.2A: Recovery of scaffold implant. A.1) Vascularity observed formed 
subcutaneously indicating ectopic angiogenesis. A.2) Bone-like nodule observed. A.3) 
Nodule measured to 2mm and processed for histological analysis.  
 
 
Figure 3.7.2B: Histological slides of control sites. Histological slides at 400x. A.1) 
Tissue sample of control side showing connective tissue only. A.2) Tissue sample of 
control side showing presence of remnants of PuraMatrixTM scaffold with no 
inflammatory cells or response. 
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Figure 3.7.2C: Histological slides of experiment sites.  A.1-A.2) Osteoid formation 
with osteoblasts at 400x.   
 
 
Figure 3.7.2D: Histological slides of experiment sites. A.1) Histological slide of 
osteoid formation at 100x. A.2 and A.3) Osteoid formation with osteoblasts present at 
edges. B.1-B.3) Osteoid formation seen at 630X showing presence of osteoblasts.  
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Number positive for bone formation/total number of implants 
 Non-seeded PuraMatrixTM HGMScs Seeded 
PuraMatrixTM 
Control 1 0/6  
Preformed 1 0/3 0/3 
Preformed 2 0/3 1/3 
Injectable 1 0/3 1/3 
Injectable 2 0/3 1/3 
Injectable 3 0/3 0/3 
   
Total 0/21 3/15 
% per group 0 0.20 
 
Table 3.7.2A: Recovered implants. Number of scaffold explants recovered from 
surgery in control and experimental sides. 
 PuraMatrixTM Only HGMSCs seeded 
PuraMatrixTM 
Tissue Sample Area (pixels) 1,787,140  2,878,668 ± 2,089,802 
Area of new bone formation 
(Pixels) 
0 354,376 ± 245,774 
Extent of new bone 
formation (%) 
0 12 ± 5.5 
 
Table 3.7.2B: Percentage of bone formation from histological analysis. Comparison 
of extent of new bone formation of HGMSCs seeded PuraMatrixTM compared to 
PuraMatrixTM scaffold only, which demonstrates evidence of bone formation. 
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CHAPTER 4: CONCLUSION AND DISCUSSION      
4.1 Discussion 
Tissue engineering involves repair and regeneration of tissue using appropriate cell 
sources and optimal culture conditions and biodegradable scaffold. Developing an 
appropriate cell- scaffold system is the key success in [14] regeneration of bone tissue. 
Additionally, special consideration needs to be taken for pediatric tissue engineering 
applications, to meet the developmental changes in the children [14, 16]. The unique 
challenge in engineering craniofacial bone tissue for pediatric population is the ability to 
recapitulate the corresponding craniofacial developmental events and needs. Therefore, 
with regards to cleft lip and palate children, our long-term goal is to enhance bone 
formation in the region of hard palate and retain proper maxillofacial growth for the 
repair of cleft palate through an appropriate use of stem cells and scaffold systems.   
 
In this study we have chosen HGMSCs as cell source. HGMSCs has highly proliferative 
and can be obtained from discarded tissue with less invasive manner. Furthermore, 90% 
of HGMSCs is derived from cranial neural crest cells [19, 20, 35], which are considered 
to be important for craniofacial development. Deficiency of neural crest cells may lead to 
the craniofacial developmental defects such as cleft lip and palate. Thus, HGMSCs 
present an appropriate stem cell source for the repair and regeneration of bone in 
craniofacial defects. Additionally, HGMSCs are capable of immunomodulatory functions 
and anti-inflammatory function [34] suggesting that they can be useful for faster healing 
and reduction of scar tissue formation.  
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The second component in bone tissue engineering is selecting a scaffold material.  A 
suitable biological scaffold can create a microenvironment niche for a given cell type. 
The main objective of the study was to develop a novel composite cell- scaffold system 
for formation of bone. PuraMatrixTM is a biologically inspired peptide hydrogel scaffold 
that can be used to create tailored 3- dimensional micro-environment with the ability to 
self-assemble in biological environments from injectable application due to it’s low 
viscosity [26, 27, 34]. Liquid as a starting material has advantageous that it can fill 
irregular shape of the defects such as cleft palate. This self-assemble peptide has 
nanofiber structure that enables the cells to adhere and proliferate the scaffold. 
PuraMatrixTM has been investigated for many tissue engineering applications, however 
with limited focus on bone regeneration [26, 58].  Table 4.1 shows the use of 
PuraMatrixTM in various in vitro and in vivo studies. In this study the novel combination 
of a self-assembled nanofibrous PuraMatrixTM – HGMSCs composite scaffold was 
characterized and bone formation ability was investigated in a subcutaneous implantation 
model within rat.   
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Literature Review of Current PuraMatrixTM Studies 
Author Year Article Cells Used Remarks 
     
Ross V et al 2014 Dental pulp tissue engineering in full-
length human root canals 
Stem cells from 
exfoliated deciduous 
teeth 
SHED differentiated into 
functional odontoblast 
Cavalcanti B et 
al 
2013 A hydrogel scaffold that maintains 
viability and supports differentiation of 
dental pulp stem cells. 
Dental pulp stem 
cells 
PuraMatrixTM and expressed 
markers of odontoblastic 
markers.  
Moradi, F et al 2012 BD PuraMatrixTM peptide hydrogel as a 
culture system for human fetal schwann 
cells in spinal cord regeneration  
Fetal Schwann Cells Used for spinal injury in 
animal.   
 
Henrisksson 
H.B. et al 
2011 Investigation of different cell types and 
gel carriers for cell-based intervertebral 
disc therapy, in vitro and in vivo studies. 
Human 
Mesenchymal Stem 
Cells, IVD cells, 
Chondrocytes 
Useful for human degenerated 
intervertebral discs.  
Kohgo T et al 2011 Bone regeneration with self-assembling 
peptide nanofiber scaffolds in tissue 
engineering for osseointegration of 
dental implants.  
Dog Mesenchymal 
Stem Cells + Platelet-
Rich Plasma 
Bone regeneration around 
dental implants.  
McGrath A et al 2010 BD PuraMatrixTM peptide hydrogel 
seeded with Schwann cells for peripheral 
nerve regeneration.  
Schwann cells Increased the rate of axonal 
regeneration across nerve 
defect.  
Nakahara H et 
al 
2010 Bone repair using a hybrid scaffold of 
self-assembling peptide PuraMatrixTM 
and polyethertherketone cage in rats.  
None Bone regeneration was 
observed when they were used 
PEEK cages 
Ortinau S et al 2010 Effect of 3D scaffold formation on 
differentiation and survival in human 
neural progenitor cells.  
Human fetal neural 
progenitor cell 
Neuronal differentiation of 
human neural progenitor cells 
has been reported.  
Maher S et al 2009 A nanofibrous cell-seeded hydrogel 
promotes integration in a cartilage gap 
model 
 
Chondrocytes Cell-seeded TGF-B3 hydrogel 
can encourage cartilage 
integration  
Yamaoka H et al 2006 Cartilage tissue engineering using human 
auricular chondrocytes embedded in 
different hydrogel materials.  
Human auricular 
chondrocytes 
Cartilage regeneration has been 
observed.  
Bokhari M et al 2005 The enhancement of osteoblast growth 
and differentiation in vitro on a peptide 
hydrogel-polyHIPE polymer hybrid 
material 
 
Rat osteoblasts RAD16-I, PuraMatrixTM, 
enhances osteoblast 
differentiation and growth 
Kisiday J et al 2002 Self-assembling peptide hydrogel fosters 
chondrocyte extracellular matrix 
production and cell division: 
implications for cartilage tissue repair. 
Chondrocytes Cartilage like structure was 
formed  
 
Table 4: Literature review of current PuraMatrixTM studies 
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In all our studies the cells cultured up to 3rd passage were used. In terms of mechanical 
stability 1% PuraMatrixTM was found to be mechanically stable, however our in vitro 
pilot studies encapsulated 0.5% PuraMatrixTM showed enhanced cell proliferation over 
1% PuraMatrixTM. 0.5% PuraMatrixTM for all our in vitro studies and established the dose 
and time of cell delivery necessary for the in vivo studies.   
 
The results of live/dead cell assay and WST demonstrated that cells are viable at all 
concentrations and the cell growth was observed till 7th after encapsulation. Over 90% of 
HGMSCs are viable and morphologically, cell growth was observed from day 1. At day 
3rd cells attained spindle shaped. The high hydrophilic nature of the hydrogel and 
incorporation of Arg-Gly-Asp proteins or the RADA groups might have provided the 
cells to adhere and proliferate with in the gel. Higher water content raises the transport 
efficiency of nutrients into wastes out of the hydrogels [59].  Thus our in vitro studies 
demonstrated that PuramatrixTM was biocompatible. Additionally light microscopic 
observations and scanning electron microscope studies revealed that the nanofiber 
structures could assist the cells to attach and formed a micro environment similar to 
extracellular matrix [60]. It is interesting to note that the cells in the center appeared like 
spherical clusters when compared to the cells at the periphery. Our results confirmed that 
PuraMatrixTM induces osteogenic differentiation in the cells treated with osteogenic 
medium. The results  of our study were in accordance with the previous reports [54]. 
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In the in vivo study cells seeded scaffold systems were transplanted to subcutaneous sites 
via two delivery methods, implant method and injectable method using 0.5% 
PuraMatrixTM based on our in vitro data and pervious studies. Nevertheless, the handling 
and implanting of preformed PuraMatrixTM to subcutaneous implantation was 
challenging, as the PuraMatrixTM would not retain its gelation form. However, the 
injectable delivery method poses significant ease in handling and delivery to 
subcutaneous sites in rats. Furthermore, we have chosen 500,000 (5 x105) cells for 
implanting as the studies indicated that the cells implanted at density of 800,000 cells/ml 
of Dental pulp stem cells (DEPC) inhibited the growth [27] phase.  
 
To visualize the extent of bone formation in subcutaneous sites on the dorsum of rats CT 
Scans were utilized. CT scans uses computer processed radiograph scans to produce 
tomographic images, or virtual slices. These cross-sectional images are used for 
diagnostic and therapeutic purposes in various medical settings in a non-invasive manner. 
Using the I-CAT software, the large series of two-dimensional radiographic images is 
generated to three-dimensional data to view scans in axial, coronal, or sagittal planes. 
This provides an advantage over traditional projection radiography, which only provides 
two-dimensional imagery. In studies using traditional projection radiography [58], only 
measurement in length can be reported. In studies using CT scans, 1-mm thick coronal 
sections can be produced from samples and scored for osseous repair/formation or 
outlined using ImageJ to present relative areas of bone per total volume [4, 8, 12, 22, 56].  
CT scans do present with limitations as “stacking” of digital slices performs volumetric 
representation and can result in artifacts. In a study by Conjero, the date from CT scans 
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were not included in analysis because of insufficient resolution of films and states that 
quality of new bone growth was evaluated by gross, radiologic, and histological 
evaluation and quantitively approximated. In more recent studies, microcomputed 
tomography scans have been more widely used in studies of this nature to quantify 
volume of interest (VOI) [12, 23, 61]. 
 
To confirm the radiographic findings, histological analysis were performed on 
PuraMatrixTM only and HGMSCs seeded PuraMatrixTM experiments. In our results, 3 
sites out of 12 experimental subcutaneous implants yield gross visual bone formation. As 
stated, prior, the preformed delivery method posed a challenge and yield less results. 
Another difficulty was identifying and excising appropriate tissue samples for analysis. 
At 4 week time point, the CT scans served as a guide to approximate the location of 
subcutaneous implants but during the surgery, without gross presence of bone, 
identifying the tissue with osseous change or inflammatory changes proved challenging. 
However, with the histological sections of bone tissue that was obtained, surface area was 
calculated using Image J software and relative area of new bone was calculated.  
 
In a recent study, Liao H et al in 2011 observed similar results to our studies implanting 
canine bone marrow derived mesenchymal stem cells in injectable thermo-responsive 
polymer hydrogel for 4 months [54]. This study observed similar in vitro results noting 
that MSCs in hydrogel showed better cell proliferation and improved osteogenic 
differentiation. The study observed ectopic bone formation using micro-CT analysis 
showing bone density mass in 2D axial and 3D view similar to the presentation in our 
	  
	  
	   51	  
study. Also, osteoid formation with osteoblasts in bone matrix and positive 
mineralization were used with H&E stains, Manson’s Trichrome stains, and von Kossa 
stains. This is also consistent with the osteoid formation also observed at week 4 in rat 
model in our study.  
 
In other recent studies, Nguyen P et al in 2009 developed alveolar defect model in rat and 
observed bone formation using scaffold combo therapy [62, 63]. Similarly to our study, 
the proposed therapeutic goals were investigated by authors to develop a critical size 
defect in the alveolus of rats from incisors to zygomatic bone. With a suitable model 
established, the authors repaired the bony defects with different combinations of either 
absorbable collage sponge or hydroxyapatite-tricalcium phosphate plus recombinant 
human bone morphogenetic protein-2 (rhBMP-2). Using micro-CT, new bone formation 
was observed in defects and seen in histological analysis. From the study, new bone 
formation plateaus at week 4 as macrophages and polymorphonuclear cells were present 
in disorganized array of fibroblasts and collagen with cuboidal-shaped osteoblasts 
observed depositing osteoid. This is consistent with our study as osteoid formation was 
observed at week 4 in our rat model. However, in comparison of histological findings, 
our osteoid formation had less prevalent osteoblast presence.   
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4.2 Conclusion  
In conclusion, our in vitro studies demonstrate that the PuraMatrixTM hydrogel enhanced 
cell proliferation and osteogenic differentiation. The null hypothesis is rejected as our in 
vivo study demonstrated the presence of osteoid like structures at week 4 when 
PuraMatrixTM hydrogel was injected with osteo-induced HGMSCs in ectopic bone 
formation rat model.  
 
Further research will need to be completed to develop a reproducible protocol and model 
in subcutaneous implantation and will investigate the potential of HGMSCs seeded 
PuraMatrixTM combination for the repair of critical size defects in hard palate of rats.  
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APPENDIX            
 
Number positive for radiopacity/total number of implants 
 Non-seeded PuraMatrixTM HGMScs Seeded 
PuraMatrixTM 
Control 1 0/6  
Preformed 1 0/3 1/3 
Preformed 2 0/3 2/3 
Injectable 1 0/3 2/3 
Injectable 2 0/3 3/3 
Injectable 3 0/3 3/3 
Total 0/21 9/15 
% per group 0 0.75 
 
 
Relative surface area of radiopacities 
 Total Surface area 
(pixels) 
Radiopacity area 
(pixels) 
Percent (%) 
CO1 0  0 0 
CP1 22130 2614 15.5 
CP31 21539 444 2 
PR11 20428 2550 11.18 
SQ2 20428 1719 8.4 
SQ3 21596 784 3.6 
    
N 5 5 5 
Mean 21224.2 1622.2 8.26 
STDEV 762.5 993 5.6 
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Number positive for bone formation/total number of implants 
 Non-seeded PuraMatrixTM HGMScs Seeded 
PuraMatrixTM 
Control 1 0/6  
Preformed 1 0/3 0/3 
Preformed 2 0/3 1/3 
Injectable 1 0/3 1/3 
Injectable 2 0/3 1/3 
Injectable 3 0/3 0/3 
Total 0/21 3/15 
% per group 0 0.20 
 
 
Surface Area of Histological Slides  
 Total Surface Area 
(pixels) 
Bone Surface Area 
(pixels) 
Percent (%) 
5222 5038848 492174 9.8 
5228 2729973 500335 18.3 
5330 867185 70619 8 
    
N 5 5 5 
Mean 21224.2 1622.2 8.26 
STDEV 762.5 993 5.6 
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